Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.1%

3 terminated out of 27 trials

Success Rate

78.6%

-7.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed with results

Key Signals

3 with results79% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (7)
P 1 (3)
P 2 (4)

Trial Status

Completed11
Recruiting5
Active Not Recruiting3
Terminated3
Withdrawn2
Enrolling By Invitation1

Trial Success Rate

78.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT06382272Not ApplicableRecruiting

A Bionic Breast Project Using Neuroprosthesis to Reduce Chronic Pain After Mastectomy

NCT06083415Not ApplicableRecruiting

Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context

NCT04333706Phase 1RecruitingPrimary

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

NCT07252986RecruitingPrimary

Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence

NCT05720039Not ApplicableActive Not Recruiting

Robotic vs. Open NSM for Early Stage Breast Cancer

NCT07370051Not ApplicableNot Yet Recruiting

Effect of Topical Oxygen and LED Light Therapy on Nipple Crack

NCT02734004Phase 1Active Not Recruiting

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

NCT04174742RecruitingPrimary

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

NCT06162351Phase 2TerminatedPrimary

A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

NCT05290402CompletedPrimary

Development of an Application-Based Digital Navigator for Perioperative Breast Surgery Patients

NCT06157879Not ApplicableCompleted

Measuring Electrical Properties of Breast Tissues

NCT07156006TerminatedPrimary

Breast Arterial Calcifications as an Imaging Biomarker of Cardiovascular Risk

NCT01078662Phase 2Completed

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

NCT05016310Not ApplicableCompletedPrimary

A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation

NCT04715802Active Not RecruitingPrimary

Options on the Breast Reconstruction Timing and Method After Removal of Polyacrylamide Hydrogel

NCT06791161Enrolling By InvitationPrimary

A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

NCT05663801Phase 2Completed

Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy

NCT00277004TerminatedPrimary

Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.

NCT03052166CompletedPrimary

Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging

NCT04524728CompletedPrimary

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Scroll to load more

Research Network

Activity Timeline